Trials / Unknown
UnknownNCT06237413
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
A Phase I/II Dose Escalation Study to Evaluating the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG2001 Tosilate Tablets in Participants With KRAS Mutated Advanced Solid Tumours
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZG2001 Tosilate Tablets | ZG2001 will be administered orally once or twice daily in a continuous regimen |
Timeline
- Start date
- 2023-08-10
- Primary completion
- 2026-02-01
- Completion
- 2026-02-01
- First posted
- 2024-02-01
- Last updated
- 2024-03-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06237413. Inclusion in this directory is not an endorsement.